Bipolar Disorder

15. Seroquel® package insert. Wilmington, DE: AstraZeneca LP, December 2009.

16.

American Psychiatric Association Work Group on Bipolar Disorder, Practice guideline for the treatment of patients with bipolar disorder, 2nd Edition, American Psychiatric Association, 2002. Available at: www.psychiatryonline.com/

pracGuide/loadGuidelinePdf.aspx?file=Bipolar2ePG_05-15- 06 (accessed February 13, 2010).

17.

Denicoff KD, Smith-Jackson EE, Disney ER, et al., Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder,

J Clin Psychiatry, 1997;58:470–78.

18.

Greil W, Ludwig-Mayerhofer W, Erazo N, et al., Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study, J Affect Disord, 1997;43:151–61.

19.

Kleindienst N, Greil W, Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study, Neuropsychobiology, 2000;42 (Suppl. 1):2–10.

20.

Bowden CL, Brugger AM, Swann AC, et al., Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group, JAMA, 1994;271:918–24.

21. 22. 23.

Rasgon N, The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the

evidence, J Clin Psychopharmacol, 2004;24:322–34.

Wang PW, Ketter TA, Becker OV, et al., New anticonvulsant medication uses in bipolar disorder, CNS Spectr, 2003;8: 930–32, 41–7.

Zajecka JM, Weisler R, Sachs G, et al., A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder, J Clin

Psychiatry, 2002;63:1148–55.

24.

Allison DB, Mentore JL, Heo M, et al., Antipsychotic- induced weight gain: a comprehensive research synthesis,

Am J Psychiatry, 1999;156:1686–96.

25. Koller EA, Doraiswamy PM, Olanzapine-associated diabetes mellitus, Pharmacotherapy, 2002;22:841–52. 26.

Lindenmayer JP, Czobor P, Volavka J, et al., Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical

antipsychotics, Am J Psychiatry, 2003;160:290–96.

27. 28. 29. 30. 31.

Wirshing DA, Boyd JA, Meng LR, et al., The effects of novel antipsychotics on glucose and lipid levels, J Clin Psychiatry, 2002;63:856–65.

Frye MA, Ketter TA, Leverich GS, et al., The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study, J Clin Psychiatry, 2000;61:9–15.

Zarate CA, Jr, Quiroz JA, Combination treatment in bipolar disorder: a review of controlled trials, Bipolar Disord, 2003;5:217–25.

Kupfer DJ, Frank E, Grochocinski VJ, et al., Demographic and clinical characteristics of individuals in a bipolar disorder case registry, J Clin Psychiatry, 2002;63:120–25.

Weisler RH, Kalali AH, Ketter TA, A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or

mixed episodes, J Clin Psychiatry, 2004;65:478–84.

32.

Weisler RH, Keck PE, Jr, Swann AC, et al., Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-

blind, placebo-controlled trial, J Clin Psychiatry,

2005;66:323–30.

33.

Ketter TA, Kalali AH, Weisler RH, A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes, J Clin Psychiatry, 2004;65:668–73.

34. Ginsberg LD, Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult

patients, Ann Clin Psychiatry, 2006;18(Suppl. 1):9–14.

35. 36.

Ginsberg LD, Carbamazepine extended-release capsules: a retrospective review of its use in children and adolescents,

Ann Clin Psychiatry, 2006;18(Suppl. 1):3–7.

Weisler RH, Kalali AH, Cutler AJ, et al., Safety of 38.

carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder, Psychiatry (Edgmont), 2008;5:49–60.

37.

Guy W, Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ No ADM 76-338), Rockville, MD: National Institute of Mental Health, 1976.

Canger R, Altamura AC, Belvedere O, et al., Conventional vs controlled-release carbamazepine: a multicentre,

double-blind, cross-over study, Acta Neurol Scand,

1990;82:9–13.

39. 40.

Haefeli WE, Meyer PG, Luscher TF, Circadian carbamazepine toxicity, Epilepsia, 1994;35:400–402.

Miller AD, Krauss GL, Hamzeh FM, Improved CNS tolerability following conversion from immediate- to

extended-release carbamazepine, Acta Neurol Scand,

2004;109:374–7.

41. 42. 43.

Elmslie JL, Silverstone JT, Mann JI, et al., Prevalence of overweight and obesity in bipolar patients, J Clin Psychiatry, 2000;61:179–84.

Berkowitz RI, Fabricatore AN, Obesity, psychiatric status,

and psychiatric medications, Psychiatr Clin North Am,

2005;28:39–54, vii–viii.

Correll CU, Manu P, Olshanskiy V, et al., Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents, JAMA, 2009;302:1765–73.

44.

Sajatovic M, Valenstein M, Blow F, et al., Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder, Psychiatr Serv, 2007;58:855–63.

45. 46. 47.

McLean A, Browne S, Zhang Y, et al., The influence of food on the bioavailability of a twice-daily controlled release

carbamazepine formulation, J Clin Pharmacol, 2001;41:183–6.

Lingam R, Scott J, Treatment non-adherence in affective

disorders, Acta Psychiatr Scand, 2002;105:164–72.

Baldessarini RJ, Tohen M, Tondo L, Maintenance treatment in bipolar disorder, Arch Gen Psychiatry, 2000;57:490–92.

10

US PSYCHIATRY Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68